Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666657 | 0.92 | EPHX2 (0.42) | EPHX2PPARGCTSLCTSSCTSB | |
| SCHEMBL6737525 | 0.90 | CTSL (0.46) | EPHX2CTSLCTSSCTSBCTSK | |
| SCHEMBL7663596 | 0.89 | CTSL (0.47) | EPHX2PPARGCTSLCTSSCTSB | |
| SCHEMBL7663180 | 0.86 | CTSL (0.41) | EPHX2PPARGCTSLCTSSCTSB | |
| SCHEMBL6740637 | 0.86 | CTSL (0.46) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6062636 | 0.85 | CTSL (0.46) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6062021 | 0.85 | PPARG (0.46) | EPHX2PPARGCTSLCTSSCTSB | |
| SCHEMBL6737451 | 0.85 | ALDH1A1 (0.50) | CTSLCTSSCTSBCTSK | |
| SCHEMBL7662418 | 0.84 | CTSL (0.46) | CTSLCTSSCTSBCTSK | |
| SCHEMBL6744437 | 0.84 | CTSL (0.46) | EPHX2CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | EPHX2 2297/4885PPARG 1955/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.